05Dec 2023
The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer

The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer

Metastasis-directed therapy (MDT) for metastatic prostate cancer (mPCa) exhibits promising outcomes, with estimated 2-year progression-free survival (PFS) of 46%, excellent local control (LC) at 97%, and low toxicity rates. While MDT allows oligorecurrent hormone-sensitive patients to defer and avoid androgen deprivation therapy (ADT)-related toxicity, its integration with systemic treatments and as part of definitive care for oligometastatic PCa holds research potential. Despite lacking randomized trials, MDT serves as an experimental approach for treatment intensification.

  • #urology

Like

Save

Share